Biotherapeutics such as monoclonal antibodies, fusion proteins, peptides and cytokines are increasingly complex, creating challenges for rapid and accurate quality characterization. Traditional liquid chromatography methods, such as size exclusion chromatography and hydrophobic interaction chromatography, often struggle with electrospray ionization mass spectrometry (MS) compatibility, slowing impurity identification.
This webinar introduces a refined matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) MS workflow that streamlines analysis, enables high-throughput screening and integrates with existing development pipelines. Attendees will gain insights into approaches that address structural complexity, enhance analytical efficiency and support faster decision-making in biotherapeutic development.
Key Learning Objectives:
Elizabeth F. Bayne, Ph.D., Senior Scientist, Merck & Co., Inc., Boston, MA, USA
Gregory F. Pirrone, Ph.D., Associate Principal Scientist, Merck & Co., Inc., Boston, MA, USA
Alexey A. Makarov, Ph.D., Senior Principal Scientist, Merck & Co., Inc., Boston, MA, USA
For Research Use Only. Not for use in clinical diagnostic procedures.